Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech (NASDAQ: ALVO) is a biotechnology company dedicated exclusively to biosimilars, and its news flow reflects the progress of a global biosimilar platform. Company updates frequently cover regulatory milestones, such as marketing authorizations in the European Economic Area, the United Kingdom and Japan for products referencing Prolia and Xgeva (denosumab), Simponi (golimumab) and Eylea (aflibercept). Press releases also highlight clinical and regulatory developments for new candidates, including submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.
Investors following ALVO news can expect regular announcements on product approvals, pipeline progress and legal or regulatory outcomes. Recent communications have described European Commission approval of AVT03, a biosimilar to Prolia and Xgeva, positive opinions from EMA committees for AVT03 and AVT05, and a settlement and license agreement enabling a future U.S. launch of AVT06, a proposed biosimilar to Eylea, subject to FDA approval. Other items include court decisions related to manufacturing activities for AVT06 and updates on applications for additional candidates such as AVT23.
Alvotech’s news flow also includes capital markets and financing transactions, such as senior unsecured convertible bond offerings and a senior term loan facility, which the company states are intended to support its research and development pipeline, manufacturing capacity and global product launches. Earnings-related press releases and business updates provide guidance ranges for revenues and adjusted EBITDA, along with commentary on order books, launch timing and investment programs.
Corporate governance and leadership changes are another recurring theme. For example, Alvotech has announced a planned CEO succession in which the founder will remain as Executive Chairman while a new Chief Executive Officer takes over day-to-day leadership. For users tracking ALVO, this news page offers a centralized view of regulatory, financial and strategic developments affecting the company’s biosimilar portfolio and global partnerships.
Summary not available.
Alvotech (NASDAQ: ALVO) has initiated a confirmatory patient study for AVT03, a biosimilar candidate to Prolia® and Xgeva®. The study aims to establish clinical similarity in efficacy and safety for treating osteoporosis in postmenopausal women. Prolia® and Xgeva® had combined sales of nearly $5.3 billion in 2021. The multicenter study will involve around 476 women, with results expected after 12 to 18 months. Alvotech, focused on biosimilars, seeks to enhance access to affordable biologic treatments globally.
Alvotech (NASDAQ: ALVO), a global biotech firm focusing on biosimilars, announced participation in two investor conferences in September 2022. The leadership team will engage in fireside chats at Citi’s 17th Annual Biopharma Conference on September 8 at 2:40 pm ET and at Morgan Stanley’s 20th Annual Global Healthcare Conference on September 12 at 2:15 pm ET. A replay of these discussions will be available on their website for 90 days. Alvotech aims to lead in the biosimilar sector with a pipeline of eight candidates addressing various medical conditions.
Alvotech (NASDAQ: ALVO), a global biotech company, has announced participation in two investor conferences in September 2022. The leadership team will engage in fireside chats at:
- Citi’s 17th Annual Biopharma Conference on September 8 at 2:40 pm ET
- Morgan Stanley’s 20th Annual Global Healthcare Conference on September 12 at 2:15 pm ET
Webcast replays will be accessible on the Investors Section of Alvotech’s website for 90 days.
Alvotech (NASDAQ: ALVO) announced it will release its financial results for Q2 and the first half of 2022 on August 31, 2022, after U.S. market close. Following the release, a business update conference call and webcast will take place on September 1, 2022, at 8:00 am ET. Alvotech specializes in biosimilar medicines, with a pipeline of eight candidates targeting various diseases. The company emphasizes growth through strategic global partnerships across multiple regions, including the U.S., Europe, and Asia.
Alvotech (NASDAQ: ALVO) is set to transition its share listing from the First North Growth Market to the Nasdaq Main Market in Iceland. This move aims to enhance visibility and potential inclusion in both Icelandic and international indexes, particularly the FTSE Global All Cap. The decision comes after Alvotech became the first Icelandic company dual-listed in the U.S. and Iceland in June 2022. The company specializes in biosimilar medicines, with a product portfolio targeting an estimated total addressable market exceeding US$85 billion.
Alvotech (NASDAQ: ALVO), the first Icelandic company dual-listed in the U.S. and Iceland, is set to move its shares to the Nasdaq Main Market in Iceland. This transition, approved by its Board of Directors, aims to enhance visibility and may lead to inclusion in international indexes like FTSE Global All Cap. Alvotech's current portfolio targets over US$85 billion market potential across several therapeutic areas, including autoimmune disorders and cancer. The move is subject to a rigorous application process and aligns with the company's ambition to strengthen its market presence.
Alvogen announced a significant district court ruling in favor of its proposed generic version of Xifaxan®, a treatment for irritable bowel syndrome with diarrhea (IBS-D). This ruling advances Alvogen's goal of providing a more affordable alternative for patients. Robert Wessman, Chairman of Alvogen, expressed satisfaction with the decision, noting its importance in delivering accessible treatment options. Alvogen specializes in developing, manufacturing, and selling both generic and branded pharmaceutical products, and is committed to expanding its market presence.
Alvotech (NASDAQ: ALVO) announced the initiation of a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®, aimed at evaluating its safety and tolerability in healthy adult males. The combined sales of Prolia® and Xgeva® approached $5.3 billion in 2021. This milestone expands Alvotech’s clinical portfolio, which now includes four products under development. The company emphasizes its mission to enhance access to affordable biologic medicines, as stated by Chief Scientific Officer Joseph McClellan.
Alvotech (NASDAQ: ALVO) has expanded its Board of Directors to include four new members, enhancing its independence and diversity. The new board members are Lisa Graver, Arni Hardarson, Linda McGoldrick, and Ann Merchant, who join existing members including Executive Chairman Robert Wessman. This strategic move aims to strengthen governance as the company transitions from private to public. The expertise of the new members in scientific, operational, and capital markets will support Alvotech's mission to improve access to biologic medicines globally.